Skip to content

Manual therapy as a prophylactic treatment for migraine. A pragmatic RCT

Manual therapy as a prophylactic treatment for migraine. A pragmatic RCT - MTmigraine research

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON49763
Enrollment
196
Registered
2019-01-08
Start date
2019-04-08
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

headache migraine

Interventions

Intervention The total treatment duration in both groups is 12 weeks. The manual therapy consists of a maximum of 9 treatments (30 minutes) during a&nbsp
period of 12 weeks with pain-reducing techniques for the high cervical&nbsp
musculature (stretching), muscle strengthening exercises for the deep neck&nbsp
flexor muscles and mobilization of the cervical and thoracic spine. The GP will treat participants as usual, based on the recommendations of the&nbsp
practice guideline for headache of the Dutch College of General Practitioners&nbsp
[8]. Apart from lifestyle advice and reassurance, the GP will provide or change&nbsp
acute medication and may provide or alter prophylactic medication. The GP will&nbsp
evaluate the treatment in consecutive appointments.

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Migraine according to the IHS classification ICHD III (2013): repeated attacks  of moderate to intense headache, usually unilateral, throbbing headache with  nausea and/or vomiting, duration of the headache attack between 4 and 72 hours,  two or more attacks per month. Increasing with physical activity such as  climbing stairs. Photofobia or phonofobia.  Tensiontype headache (TTH) ICHD III (2013) that can be distinguished by the  participant. Migraine with aura symptoms such as neck pain and additional presence of vision  changes , tingling or numbness in lips, face, or hand (onesided), one-sided muscle weakness, or  impaired speech.  Migraine more than 1 year present and participants who are stable on  prophylactic medication.  Age: between 18 years 65 years Participant is able to fill in questionnaires (understand Dutch language)

Exclusion criteria

Exclusion criteria: Exclusion criteria are suspected malignancy, pregnancy, cerebrovascular  disease, degenerative central nervous system diseases, medication-overuse  headache, a current diagnosis of depression or other severe psychiatric  disease, rheumatoid arthritis, serious or systemic infection, fever, or change  in medication for migraine within three months before the study, and having  received MT treatment for migraine up to three months prior to the start of the  study.

Design outcomes

Primary

MeasureTime frame
The primary outcome of the study is the number of migraine days, administrated by the participant in a headache diary during the four weeks prior to the follow-up assessments (Tfelt-Hansen 2012). A migraine day is defined as a day with migraine characteristics according to the IHS classification ICDH III for longer than four hours, or a headache that resolves with the intake of triptans or ergotamine within two hours of intake.

Secondary

MeasureTime frame
All of the secondary outcome measures will be assessed at 12, 26 and 52 weeks follow-up assessments. The secondary outcome measures are: 1. Number of migraine attacks per four weeks, administrated in a headache diary during the four weeks before follow-up measurements (Tfelt-Hansen 2012). Migraine attacks will be considered as separate attacks if 48 hours without headache is reported in the headache diary between migraine days. 2. Pain intensity of migraine, assessed on an 11 point numerical rating scale (0 = no pain, 10 = most severe pain) (Williamson 2005). 3. Neck pain intensity, assessed on an 11 point numerical rating scale (0 = no pain, 10 = most severe pain). 4. Medication use in number of doses per 4 weeks of simple analgesics (e.g., paracetamol), NSAIDs, acute migraine medication (triptans and ergotamines) or prophylactic medication. Change of medication will be administrated and reported. 5. Responder rate will be measured by the number of migraine days before vs. after treatment, dichotomized into *50% reduction or not (Tfelt-Hansen 2012). 6. Disability, assessed by the HIT-6 questionnaire. The HIT-6 consists of 6 questions measuring pain intensity, social functioning, role functioning, vitality, cognitive functioning and psychological distress on a 5 point ordinal rating scale (never, to always). Internal consistency is considered high (Cronbach's alpha 0.82 to 0.90), and test-retest reliability is fair (ICC 0.77) (Yang 2011). The Dutch version of the HIT-6 questionnaire has shown to be a valid and reliable tool to measure the impact of migraine (Martin 2004). 7. The endurance of the neck flexor muscles will be scored as the number of seconds the participant can raise his head from the table when lying in supine position as described by Harris et al. (2005). 8. Cutaneous allodynia (CA) will be evaluated with the 12 item allodynia symptom checklist (ASC-12). This questionnaire consists of 12 questions about cutaneous hypersensitivity in the cervical ceph

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)